Time trends in overall survival (OS) gain in advanced non-small-cell lung cancer (NSCLC).

被引：0
|
作者：
Saad, Everardo D.
Buyse, Marc E.
Jassem, Jacek
机构：
[1] Dendrix Res, Sao Paulo, Brazil
[2] Int Inst Drug Dev, Louvain, Belgium
[3] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19144
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
    Rutkowski, Jacek
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Role of time to progression as a surrogate marker for overall survival in patients with advanced non-small-cell lung cancer (NSCLC)
    Hotta, K.
    Kiura, K.
    Fujiwara, Y.
    Takigawa, N.
    Tabata, M.
    Ueoka, H.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Nondisruptive mutations of TP53 and overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients (p)
    Costa, Enric Carcereny
    Bertran-Alamillo, Jordi
    Molina-Vila, Miguel Angel
    Gervais, Radj
    Massuti, Bartomeu
    Bonanno, Laura
    Moran, Teresa
    Majem, Margarita
    Felip, Enriqueta
    Garcia-Campelo, M. Rosario
    Vergnenegre, Alain
    Ramirez, Santiago Viteri
    Gasco, Amaya
    Wannesson, Luciano
    Mayo-de las Casas, Clara
    Pujantell-Pastor, Laia
    Favaretto, Adolfo G.
    Karachaliou, Niki
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Overall survival benefit in advanced non-small-cell lung cancer
    Owen, Olwen Glynn
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (07) : 379 - 379
  • [5] Distribution of Immune Markers and Their Association with Overall Survival and Time to Progression in Non-Small-Cell Lung Cancer (NSCLC)
    Kuykendall, Andrew T.
    Khalil, Farah
    Haura, Eric
    Antonia, Scott J.
    Schabath, Matthew
    Gabrilovich, Dmitry
    Creelan, Ben
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S268 - S269
  • [6] Nutritional Risk Status Predicts Overall Survival of Mexican Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Campos-Gomez, S.
    Valdez-Andrade, J. J.
    Esquivel-Gutierrez, J.
    Jaimes Alpizar, E.
    Pacheco-Cuellar, G.
    Campos-Gomez, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S291 - S291
  • [7] Cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Pirker, Robert
    LUNG CANCER, 2012, 77 : S13 - S14
  • [8] Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2233 - S2234
  • [9] Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer
    Presley, Carolyn J.
    Tang, Joy
    Benedict, Jason
    Grogan, Madison
    Reisinger, Sarah
    Janse, Sarah
    Wong, Melisa L.
    Arrato, Nicole A.
    Davenport, Ashley
    Shields, Peter G.
    Andersen, Barbara L.
    LUNG CANCER, 2024, 196
  • [10] Paclitaxel cisplatin in advanced non-small-cell lung cancer (NSCLC)
    Pirker, R
    Krajnik, G
    Zochbauer, S
    Malayeri, R
    Kneussl, M
    Huber, H
    ANNALS OF ONCOLOGY, 1995, 6 (08) : 833 - 835
12345